Biogen Idec Inc (BIIB): Today's Featured Drugs Laggard

Biogen Idec ( BIIB) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.3%. By the end of trading, Biogen Idec fell $3.58 (-1.6%) to $218.07 on light volume. Throughout the day, 918,017 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,491,000 shares. The stock ranged in price between $217.50-$225.22 after having opened the day at $223.38 as compared to the previous trading day's close of $221.65. Other companies within the Drugs industry that declined today were: Biota Pharmaceuticals ( BOTA), down 70.1%, Mast Therapeutics ( MSTX), down 37.2%, Redhill Biopharma ( RDHL), down 20.0% and Oramed Pharmaceuticals ( ORMP), down 10.3%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $51.6 billion and is part of the health care sector. Shares are up 48.6% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Biostar Pharmaceuticals ( BSPM), up 20.1%, Alcobra ( ADHD), up 15.5%, Epizyme ( EPZM), up 14.3% and Inovio Pharmaceuticals ( INO), up 11.8% , were all gainers within the drugs industry with Eli Lilly and Company ( LLY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.